News
Aurinia announces licensing partner Otsuka filed initial marketing authorization application (MAA) for voclosporin with the European Medicines Agency (EMA) for lupus nephritis.
Aurinia Pharmaceuticals Inc. has announced that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. , filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis (LN) to the European Medicines Agency (EMA).
LN is a complication of the autoimmune disease systemic lupus erythematosus (SLE) that seriously impacts the kidneys.
In January 2021, the FDA approved voclosporin in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active LN and it is currently available in the U.S. under the brand name Lupkynis.
Condition: Lupus Nephritis
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins